Investor FAQs

What is the status of the proposed merger with Aditxt?

On December 23, 2024, Evofem cancelled the planned special meeting related to the proposed transactions and withdrew from consideration by Evofem stockholders the proposals that were set forth in its preliminary proxy statement filed with the SEC on September 23, 2024.

What is the record date for the Stockholder Meeting to vote on the proposed Aditxt merger?

On December 23, 2024, Evofem cancelled its planned special meeting related to the proposed transactions and withdrew from consideration by Evofem stockholders the proposals that were set forth in its preliminary proxy statement filed with the SEC on September 23, 2024.

What does Evofem do?

Evofem Biosciences commercializes innovative products to address unmet needs in women's sexual and reproductive health. We currently generate revenues through the sale of our FDA-approved products:

- PHEXXI® (lactic acid, citric acid, and potassium bitartrate). Our hormone-free, on-demand prescription contraceptive vaginal gel comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com.

- SOLOSEC® (secnidazole) 2 g oral granules. Our FDA-approved antimicrobial agent provides a complete course of therapy with just one oral dose for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections. Learn more at solosec.com.

 

What is Evofem’s ticker symbol?

EVFM.

Where does Evofem's common stock trade?

Evofem's common stock has traded on the OTCQB Venture Market since October 3, 2022. Quotes and related Company information are available at www.otcmarkets.com.

 

How can I invest in Evofem?

You must contact a registered broker to invest in Evofem (OTCQB: EVFM) common stock.

What is the CUSIP number for Evofem?

Effective May 18, 2023, Evofem's CUSIP is 30048L302.

What year was Evofem incorporated?

Evofem, Inc. was incorporated in 2009. However, Evofem, Inc.'s ultimate parent company Evofem Biosciences, Inc. was incorporated in 2015

How did Evofem become a public company?

Evofem became a public company through a reverse merger with Neothetics, Inc., which closed January 17, 2018.

How many shares of Evofem are outstanding?

As of November 8, 2024, there were approximately 100,328,686 shares of Evofem common stock, 2,017 shares of Series E-1 Convertible Preferred stock, and 23,540 shares of Series F-1 Preferred stock issued and outstanding. Please refer to the SEC filings webpage of the Investor section of our website for subsequent updates.

 

Who is Evofem’s transfer agent for ordinary shares?

Pacific Stock Transfer
6725 Via Austi Pkwy Suite 300
Las Vegas, NV 89119

Pacific Stock Transfer’s business hours are 8:00 a.m. to 4:30 p.m. PST, Monday through Friday. Connect with them:

I hold Evofem Biosciences common warrants. How do I exercise these warrants?

Please contact ir@evofem.com for instructions on how to exercise warrants before wiring funds to the Company.

May 2018 warrants (only) may be exercised directly through Philadelphia Stock Transfer by submitting a Deposit/Withdrawal by Custodian (DWAC) withdrawal on the warrants and a DWAC deposit on the common once exercise funds were confirmed and received. For more information, please contact Bob Winterle at Philadelphia Stock Transfer: bwinterle@philadelphiastocktransfer.com / 484.416.3124.

Who is Evofem’s independent public accounting firm?

BPM LLP 

Who is Evofem’s corporate counsel?

Procopio, Cory, Hargreaves & Savitch LLP

When is the stockholder meeting held?

The dates for stockholder meetings are determined by the Board of Directors and will be disclosed in our proxy filings with the SEC, which are available through the SEC Filings tab of the Investors section of our website (click here).

Our most recent Annual Meeting of Stockholders was held on September 14, 2023.

Are you on a calendar or fiscal year?

Evofem is on a calendar year that ends December 31.

How can I get Evofem’s financial documents?

Please refer to the SEC filings webpage of the Investor section of our website. 

How can I contact Evofem’s investor relations department?

Please contact Amy Raskopf, Senior Vice President of Investor Relations, at araskopf@evofem.com or by phone at 917.673.5775.

How can I get added to Evofem’s mailing list?

You can sign up for e-mail alerts notifying you of new press releases, SEC filings or corporate actions and events on the “Investor Contacts and Alerts” page of the Investor section of our website.